External validation of a heart failure risk score in patients with acute myeloid leukemia. Issue 2 (28th January 2023)

• Record Type: Journal Article
• Authors: Doukas, Peter G.; Cascino, Gregory J.; Meng, Zhiying; Baldridge, Abigail S.; Kang, Yu; Scherrer-Crosbie, Marielle; Akhter, Nausheen
• Is Part Of: Leukemia & lymphoma. Volume 64:Issue 2(2023)
• Page Start: 445
• Page End: 453
• Publication Date: 2023-01-28
• Subjects: Acute myeloid leukemia -- external validation -- heart failure -- risk score -- global longitudinal strain -- anthracycline chemotherapy; Leukemia -- Periodicals; Lymphomas -- Periodicals; 616.99419
• DOI: 10.1080/10428194.2022.2140289
• Languages: English
• ISSNs: 1042-8194

Abstract

Abstract: A 21-point risk score for heart failure (HF) has been developed for patients with acute myeloid leukemia (AML), stratifying patients into three groups: low, moderate, and high-risk. In this study, 193 patients with AML treated with anthracycline-based therapy were stratified using the risk score, and its prognostic utility for HF events and all-cause mortality at one year of follow-up were evaluated. HF occurred in 18% (34/193) of anthracycline-treated patients. Global longitudinal strain (GLS) was more negative among patients without HF events (−19 ± 3 vs. −17 ± 4%). One year incidence of HF was increased in the higher risk groups: 12% of low-risk, 24% of moderate-risk, and 50% of high-risk ( p < 0.001). However, a higher risk score was not associated with an increased risk of all-cause mortality. This study provides external validation of a 21-point risk score for HF events but not all-cause mortality at one year in patients with AML.